BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 63 filers reported holding BRIDGEBIO PHARMA INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $86,712 | -30.7% | 2,804,394 | -9.5% | 0.28% | -36.5% |
| Q4 2023 | $125,070 | +497.0% | 3,098,082 | +290.0% | 0.45% | +475.6% |
| Q3 2023 | $20,949 | -99.9% | 794,401 | -0.3% | 0.08% | -12.4% |
| Q3 2021 | $37,340,000 | -25.5% | 796,668 | -3.1% | 0.09% | -26.4% |
| Q2 2021 | $50,110,000 | -33.9% | 822,018 | -33.2% | 0.12% | -37.3% |
| Q1 2021 | $75,823,000 | -0.7% | 1,230,885 | +14.6% | 0.19% | -4.5% |
| Q4 2020 | $76,370,000 | +231.1% | 1,073,966 | +74.7% | 0.20% | +173.0% |
| Q3 2020 | $23,064,000 | -24.0% | 614,724 | -34.0% | 0.07% | -30.2% |
| Q2 2020 | $30,351,000 | +5.8% | 930,733 | -5.9% | 0.11% | -16.5% |
| Q1 2020 | $28,689,000 | -14.7% | 989,267 | +3.1% | 0.13% | +13.4% |
| Q4 2019 | $33,619,000 | +95.5% | 959,184 | +19.8% | 0.11% | +89.8% |
| Q3 2019 | $17,193,000 | +29.2% | 800,804 | +62.3% | 0.06% | +37.2% |
| Q2 2019 | $13,305,000 | – | 493,342 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $60,317,000 | 40.05% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $308,746,000 | 6.20% |
| M28 Capital Management LP | 513,300 | $5,102,000 | 5.33% |
| GREAT POINT PARTNERS LLC | 1,050,000 | $10,437,000 | 2.51% |
| Octagon Capital Advisors LP | 933,743 | $9,281,000 | 1.60% |
| HHLR ADVISORS, LTD. | 5,362,014 | $53,298,000 | 1.40% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $264,613,000 | 1.22% |
| Cormorant Asset Management, LP | 1,469,179 | $14,604,000 | 1.02% |
| Fernwood Investment Management, LLC | 204,550 | $2,033,000 | 0.86% |
| TANG CAPITAL MANAGEMENT LLC | 585,424 | $5,819,000 | 0.71% |